JOSD1

Across TCGA pan-cancer cohorts, JOSD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated JOSD1 data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher JOSD1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated JOSD1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where JOSD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	1.000	0.202	.003	13	view →
UCEC	OS	Quartile	All	0.764	1.000	.009	12	view →
PDAC	OS	Median	All	0.852	1.000	.013	6	view →
HNSC	OS	Tertile	All	1.000	0.893	.035	4	view →
LSCC	DFS	Median	II,III,IV	0.673	0.924	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

JOSD1–CCRCC (DFS)

Open the CCRCC breakdown →